Sign inJoin waitlistJoin the waitlist

Leia Nghiemphu

Associate Professor of Clinical Neurology, Director of UCLA Neuro-Oncology Clinical Service · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · ·

History

UCLA Neuro-Oncology
2003–2006
Neurology
Stanford Health Care
2000–2003
Beth Israel Medical Center-North Division
1999–2000
Albert Einstein College of Medicine
1995–1999

Research

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Nature Medicine · 2019 · 1,142 citations
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
PLoS Medicine · 2008 · 484 citations
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
Journal of Clinical Oncology · 2011 · 377 citations

Timothy Cloughesy
145 papers
Albert Lai
128 papers · 1 as a fellow
Whitney Pope
85 papers
Linda Liau
81 papers
Noriko Salamon
37 papers
William Yong
31 papers
Paul Mischel
20 papers
Richard Everson
15 papers
Richard Green
14 papers
Kevin Leu
11 papers · 1 as a resident
IM
Ingo Mellinghoff
9 papers
Harley Kornblum
8 papers

Clinical trials

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Principal investigator · Recruiting · Phase 1
Jonsson Comprehensive Cancer Center
2025–2028
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Principal investigator · Withdrawn · Phase 1
Jonsson Comprehensive Cancer Center
2021–2026
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Principal investigator · Completed · Phase 2
Jonsson Comprehensive Cancer Center
2010–2023
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Site PI · Recruiting · Phase 2
Scott R. Plotkin, MD, PhD
2020–2030